Science-First. Mission-Driven.
We founded Mojo BioPharma on a simple conviction: that the most important diseases of our time — aging and cancer — are solvable with the right science, the right team, and the relentless will to push forward.
A magical power or charm; an ability to achieve success through a special quality or talent. At Mojo BioPharma, it is the belief that transformative science — pursued with courage and conviction — can unlock the full potential of human health.
Our Mission
Mojo BioPharma exists to transform human health by advancing the frontiers of longevity science and precision oncology. We operate with the urgency of patients who need better options and the rigor of scientists who demand evidence. Our dual-division structure allows us to pursue two of the most consequential challenges in medicine simultaneously — extending healthy human lifespan and defeating cancer at the molecular level.
Team
Leadership
Dr. Johe is a pioneer in stem cell technology platforms and Klotho biology with over 25 years of research. He previously led the neuronal stem cell programs at the NIH and Neuralstem, a company he founded. Kalr has authored 60+ peer-reviewed publications on aging mechanisms. Karl manages the neuroscience and longevity programs at Longevity Sciences.
Mr. LeBlanc manages the business activities of Mojo BioPharma. Jeff is a serial entrepreneur and has been managing director and/or President of several successful companies He brings deep expertise in public company compliance and reporting. He graduated from MIT in chemical engineering and went on to get a MBA from Harvard Business School.
Dr. Sinkule is the founder and leader of Mojo BioPharma. He is a serial entrepreneur having formed and funded multiple companies in the life sciences field. With over 40 years of drug and biologics experience in all phases of drug development, Dr. Sinkule is a highly regarded expert in antibody therapeutics, diagnostics, cell and gene therapies across many different fields of use. He has been the leader of several private and public (NASDAQ listed) companies and has two decades of biotech finance experience. Recently, he led over $100M in equity financings and multiple strategic partnerships with major pharma.
Scientific Advisory Board